---
title: Identify markers predicting Parkinson progression
nct_id: NCT02305147
status: RECRUITING
sponsor: Institut National de la Santé Et de la Recherche Médicale, France
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT02305147"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02305147"
last_fetched: "2026-05-10T14:06:28.345Z"
source: "Parkinson's Pathways (curated)"
---
# Identify markers predicting Parkinson progression

**Goal (in five words):** Identify markers predicting Parkinson progression

**Official Title:** Etude Des Facteurs Prédictifs De L'apparition Et De L'évolution De La Maladie De Parkinson

**Trial ID:** [NCT02305147](https://clinicaltrials.gov/study/NCT02305147)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Target Enrollment:** 360 participants
- **Start Date:** 2014-11-06
- **Completion Date:** 2029-11-06
- **Conditions:** Parkinson Disease
- **Interventions:** Clinical, biological and imaging followup
- **Intervention Types:** OTHER

## Summary For Families

The goal is to find clinical, biological, imaging and genetic markers that predict who will develop Parkinson's and how quickly the disease will progress. Participants have regular clinical exams, blood and genetic tests, MRI scans and dopamine transporter SPECT imaging, with SPECT measuring loss of dopamine nerve terminals and MRI checking brain structure so researchers can link symptoms to measurable changes over time. The trial is enrolling adults 18 and older in four groups: people with recent idiopathic Parkinson's diagnosed under 3 years ago, people with confirmed PD gene mutations, people at higher risk such as those with idiopathic REM sleep behavior disorder or relatives of genetically confirmed patients, and healthy volunteers. Key requirements include a normal basic cognitive screen, no contraindication to MRI or SPECT, and no drug-induced or atypical parkinsonism or recent neuroleptic use.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* All subjects: Male or female age 18 years and older, MMSE score \> 26, negative pregnancy test in potentially child-bearing women (contraindication to SPECT with DatScan).
* Idiopathic Parkinson disease subjects: diagnosis confirmed according to UK Parkinson's Disease Society Brain Bank criteria (UKPDSBB); disease duration less than 3 years.
* Genetic Parkinson disease subjects: parkinson diagnosis confirmed and mutation in parkin, LRRK2, SNCA or GBA genes.
* Prodromal subjects: subjects with identified relative with PD genetically confirmed or subjects with diagnosis of idiopathic Rem sleep Behavior Disorder (iRBD); neurological examination normal (no signs of parkinsonism).
* Healthy subjects: neurological examination normal

Exclusion Criteria:

* All subjects: Psychiatric disorder or any progressive life-threatening disease, impairment precluding appropriate information and instructions given concerning participation to the study; contra-indication to MRI or SPECT scan.
* Parkinson disease subjects: no dopamine transporter deficit at SPECT scan; parkinsonism induced by neuroleptics; neuroleptics intake within 6 months; atypical parkinson syndrom (MSA, PSP, CBD...)
* Parkinson disease subjects with mutation in Parkin, LRRK2, SNCA or GBA gene: atypical parkinson disease syndromes due to either drugs (e.g., metoclopramide, flunarizine, neuroleptics) or metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy) or currently taking neuroleptics or has taken neuroleptics within 6 months of baseline or any biological anomaly.
```

## Locations (1)

- Hôpital Pitié-Salpêtrière, Paris, France _(48.8534, 2.3488)_

## Central Contacts

- Marie VIDAILHET, PhD — (CONTACT) — marie.vidailhet@psl.aphp.fr

---

*Canonical: https://parkinsonspathways.com/trial/NCT02305147*  
*HTML version: https://parkinsonspathways.com/trial/NCT02305147*  
*Source data: https://clinicaltrials.gov/study/NCT02305147*